Video

Dr. Bardia on the Results of the ASCENT Trial in Previously Treated Metastatic TNBC

Aditya Bardia, MD, MPH, discusses the results of the randomized phase 3 ASCENT trial in previously treated, metastatic triple-negative breast cancer.

Aditya Bardia, MD, MPH, director of Precision Medicine at the Center for Breast Cancer and founding director of the Molecular and Precision Medicine Metastatic Breast Cancer Clinic, Massachusetts General Hospital Cancer Center, and assistant professor of medicine, Harvard Medical School, discusses the results of the randomized phase 3 ASCENT trial in previously treated, metastatic triple-negative breast cancer (TNBC).

Findings from the study, which were presented virtually during the 2020 ESMO Congress, revealed that patients who received the antibody-drug conjugate sacituzumab govitecan-hziy (Trodelvy) had a median progression-free survival of 5.6 months compared with 1.7 months with standard chemotherapy (HR, 0.41; 95% CI, 0.32-0.52; P < .0001).

This translates to a 59% reduction in the risk of disease progression or death with sacituzumab govitecan versus chemotherapy in this patient population, meeting the primary end point of the study, explains Bardia.

In April 2020, the FDA granted an accelerated approval to sacituzumab govitecan for the treatment of adult patients with metastatic TNBC who have received at least 2 prior therapies for metastatic disease.

Related Videos
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec
Sheldon M. Feldman, MD
Dana Zakalik, MD
Alberto Montero, MD, MBA, CPHQ
Jairam Krishnamurthy, MD, FACP
Deena Mary Atieh Graham, MD
Sheldon M. Feldman, MD
Sheldon M. Feldman, MD
In this episode of OncChats: Empowering Community Cancer Care, Dr. Rai emphasizes the importance of community outreach and support for patients with cancer, highlighting the need for holistic care that addresses both physiological and psychological aspects of treatment while reinforcing the value of strong relationships between primary care physicians and specialists.
In this episode of OncChats: Empowering Community Cancer Care, Dr. Woodworth sheds light on the “Road to Recovery” survivorship program at Henry Mayo, which supports cancer survivors by providing them with fitness, education, and mental health resources, and underscores the importance of mentorship programs for community providers to ensure equitable cancer care.